BioLife Solutions (BLFS) Gets a Buy from Northland Securities

Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions today and set a price target of $31.00. The company’s shares closed yesterday at $26.30.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, Brainsway, and BioLife Solutions. According to TipRanks, Byrnes has an average return of -4.4% and a 38.11% success rate on recommended stocks.

In addition to Northland Securities, BioLife Solutions also received a Buy from Lake Street’s Thomas Flaten in a report issued yesterday. However, on September 27, TR | OpenAI – 4o reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).

Based on BioLife Solutions’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $25.42 million and a GAAP net loss of $15.84 million. In comparison, last year the company earned a revenue of $19.72 million and had a GAAP net loss of $20.72 million

Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Most recently, in August 2025, Todd Berard, the CMO of BLFS sold 10,000.00 shares for a total of $255,300.00.